Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Raw Materials (2023 - 2025)

Historic Raw Materials for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $6.0 million.

  • Genmab A's Raw Materials rose 50000.0% to $6.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.0 million, marking a year-over-year increase of 50000.0%. This contributed to the annual value of $6.0 million for FY2025, which is 50000.0% up from last year.
  • As of Q4 2025, Genmab A's Raw Materials stood at $6.0 million, which was up 50000.0% from $1.0 million recorded in Q4 2024.
  • Over the past 5 years, Genmab A's Raw Materials peaked at $6.0 million during Q4 2025, and registered a low of $1.0 million during Q4 2024.
  • In the last 3 years, Genmab A's Raw Materials had a median value of $2.0 million in 2023 and averaged $3.0 million.
  • As far as peak fluctuations go, Genmab A's Raw Materials plummeted by 5000.0% in 2024, and later surged by 50000.0% in 2025.
  • Quarter analysis of 3 years shows Genmab A's Raw Materials stood at $2.0 million in 2023, then tumbled by 50.0% to $1.0 million in 2024, then skyrocketed by 500.0% to $6.0 million in 2025.
  • Its Raw Materials stands at $6.0 million for Q4 2025, versus $1.0 million for Q4 2024 and $2.0 million for Q4 2023.